These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 29110655

  • 1. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
    Rutkowski P, Magnan H, Chou AJ, Benson C.
    BMC Cancer; 2017 Nov 06; 17(1):717. PubMed ID: 29110655
    [Abstract] [Full Text] [Related]

  • 2. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep 06; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 3. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
    Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC.
    BMC Cancer; 2016 Jan 15; 16():22. PubMed ID: 26772734
    [Abstract] [Full Text] [Related]

  • 4. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B.
    Ann Surg Oncol; 2012 May 15; 19(5):1551-9. PubMed ID: 22065192
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
    Li J, Gao J, Hong J, Shen L.
    Future Oncol; 2012 May 15; 8(5):617-24. PubMed ID: 22646775
    [Abstract] [Full Text] [Related]

  • 6. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D, PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).
    Lancet Oncol; 2016 May 15; 17(5):632-41. PubMed ID: 27068858
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD.
    Pediatr Blood Cancer; 2009 Jul 15; 52(7):767-71. PubMed ID: 19326424
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.
    Ann Oncol; 2016 Sep 15; 27(9):1794-9. PubMed ID: 27371698
    [Abstract] [Full Text] [Related]

  • 9. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Murray M, Hatcher H, Jessop F, Williams D, Carroll N, Bulusu R, Judson I.
    Pediatr Blood Cancer; 2008 Feb 15; 50(2):386-8. PubMed ID: 17729245
    [Abstract] [Full Text] [Related]

  • 10. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.
    JAMA; 2012 Mar 28; 307(12):1265-72. PubMed ID: 22453568
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
    Yang W, Li K, Yu J, Shou C, Zhang Q, Hong Y, Sun J, Yu H, Gao Y, Shen Q, Zhao Z, Zheng S.
    Scand J Gastroenterol; 2018 Mar 28; 53(10-11):1328-1334. PubMed ID: 30346846
    [Abstract] [Full Text] [Related]

  • 12. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Reichardt P, Reichardt A.
    Zentralbl Chir; 2011 Aug 28; 136(4):359-63. PubMed ID: 21863513
    [Abstract] [Full Text] [Related]

  • 13. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 28; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 14. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.
    Chen YY, Yeh CN, Cheng CT, Chen TW, Rau KM, Jan YY, Chen MF.
    World J Gastroenterol; 2011 Apr 28; 17(16):2113-9. PubMed ID: 21547131
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
    Martínez-Marín V, Maki RG.
    Gastroenterol Clin North Am; 2016 Sep 28; 45(3):477-86. PubMed ID: 27546844
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J.
    BMC Cancer; 2012 Mar 22; 12():107. PubMed ID: 22439647
    [Abstract] [Full Text] [Related]

  • 19. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD.
    Lancet Oncol; 2013 Nov 22; 14(12):1175-82. PubMed ID: 24140183
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
    Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC, Fumagalli E, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD.
    Cancer; 2015 May 01; 121(9):1405-13. PubMed ID: 25641662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.